Currently, there are myriad studies investigating improvements in surgical methods for anterior cruciate ligament reconstruction (ACLR), for example, bone tunnel construction and placement, graft choices, graft preparation, and graft fixation.^[@bibr3-2325967114526687],[@bibr19-2325967114526687],[@bibr21-2325967114526687]^ Yet, perfect surgical techniques still need an adequate biological healing response to yield good clinical outcomes. Reports have attributed poor graft healing as one of the causes leading to nontraumatic ACLR failure.^[@bibr5-2325967114526687],[@bibr15-2325967114526687]^ Graft healing of ACLR involves slow biological processes,^[@bibr18-2325967114526687]^ which are primarily attributed to graft remodeling such as intratunnel graft incorporation and intra-articular graft ligamentization.^[@bibr50-2325967114526687]^ Previous approaches to enhance the healing at the graft-tunnel interface include the use of mesenchymal stem cells, growth factors, biomaterials, or biophysical intervention. Most of these preclinical animal studies still need further scrutiny to see if further clinical trials were worthwhile. An overall picture of the current development on biological modulation for ACLR would be obtained by performing a systematic review of both clinical and preclinical evidence. By critical appraisal on the study quality and significance of these studies, a better understanding on the effectiveness of biological modulation on ACLR can be attained. A summary of the proposed mechanisms of the treatment effect may also provide insights for further development of new approaches of biological modulation for ACLR.

The purposes of this study were (1) to perform a systematic review on the effectiveness of biological modulation to promote healing in ACLR, (2) to evaluate different biological modulations based on the proposed mechanisms, and (3) to evaluate the clinical significance of preclinical animal studies on biological modulation of ACLR.

Methods {#section1-2325967114526687}
=======

Study Selection {#section2-2325967114526687}
---------------

The inclusion criteria for studies in this systematic review consisted of the following:**Study types:** Clinical studies and animal studies. Studies included in searched reviews or systematic reviews were also tracked.**Study group:** Patients with ACL tears who received surgical treatment; animal models with ACL injuries.**Intervention type:** Drugs, growth factors, cells, interface biomaterials to promote graft incorporation, and biophysical interventions that stimulate healing.**Language:** No restriction.

The exclusion criteria consisted of the following:**Study types:** Studies of natural healing without intervention, in vitro studies, and studies without a control group.**Article type:** Articles other than original research articles.**Intervention types:** Interventions not related to biological modulation to promote healing, such as surgical treatments (direct sutures, fixation methods), artificial grafts or screws that do not aim at biological modulation, anesthetics, analgesics, and rehabilitation protocols.

Search Strategies {#section3-2325967114526687}
-----------------

Systematic searches were carried out in January 2013 using PubMed, Ovid, and Scopus databases. The keywords in combination with search operants were as follows: (ACL OR anterior cruciate ligament) AND (growth factor OR stem cell OR drug OR biomaterial OR biophysical intervention). A postsearch filtering with keywords *reconstruction*, *reconstructive*, and *healing* in the titles was used to facilitate the identification of relevant studies. Studies with biological modulation on ACL lesion without reconstructive surgery were also identified by screening the titles. The search results from 3 different databases were merged, and duplicate studies were removed. Application of inclusion/exclusion criteria on the search results was started by screening the title and then the abstracts. The full text of the filtered articles was then obtained for data extraction, such as publication years, first author, type of modulation, animal model, sample size, follow-up time, key outcome measures, and major findings. A flowchart of the search results is shown in [Figure 1](#fig1-2325967114526687){ref-type="fig"}. After the original search in January 2013, an updated search was conducted in January 2014 to cover publications from January 2013 to January 2014. The search criteria remained the same as the original search.

![Flowchart showing results of database search, article elimination, and final inclusion performed in January 2013. Results of the updated search performed in January 2014 are reported separately in the Results section.](10.1177_2325967114526687-fig1){#fig1-2325967114526687}

Assessment of Study Quality {#section4-2325967114526687}
---------------------------

Scientific evidence for effectiveness of biological modulation of healing of ACL injuries includes information from both clinical trials and preclinical animal studies. Clinical trials (level 1 or 2) are regarded as "high" evidence level, and the Critical Appraisal Skill Programme (CASP) appraisal form was used to evaluate the study quality. Animal studies are of lower evidence level, and they can be further stratified into 5 ranks based on outcome measures:

A.  Quantitative outcome measures analogous to clinical outcome measures (eg, knee laxity, activity level, and gait)

B.  Mechanical test of graft complex strength (ultimate load, linear stiffness) as quantitative outcome measures

C.  Biochemical measurement as quantitative outcome measures

D.  Semiquantitative imaging/histological assessment

E.  Qualitative imaging/histological assessment

The quality of animal studies was assessed according to the criteria adapted from the checklist of Hooijmans et al,^[@bibr22-2325967114526687]^ provided in [Table 1](#table1-2325967114526687){ref-type="table"}.

###### 

Assessment Criteria of Methodological Quality of Animal Studies of ACLR*^a^*

![](10.1177_2325967114526687-table1)

        Criteria                                                   Score                            Remarks
  ----- ---------------------------------------------------------- -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\.   Unit of sample                                             Unilateral: 1 Bilateral: 0       Studies with bilateral operation may regard each limb as an independent sample and assign them to different treatment groups. Unless the sample unit was specified as number of animal instead of number of limbs, animal studies with unilateral operation with animal as sample unit will be better.
  2\.   Standardization of surgical procedure                      Yes: 1 No: 0                     Standardization of surgical procedure includes the descriptions about graft harvest, approaching intra-articular region, drilling tunnels, graft tensioning, and fixation method. Studies with these descriptions would be regarded as standardized procedures as major surgical variables are controlled.
  3\.   Description of postoperative complications and follow-up   Yes: 1 No: 0                     Records of postoperative complications such as broken sutures, wound infection, and early death are regarded to have better study quality.
  4\.   Report of failure mode in mechanical test                  Yes: 1 No: 0                     Since most ACLR animal studies used mechanical testing as the primary outcome, report of failure mode is important to reveal the quality and the implications of the mechanical tests.
  5\.   Variation (ratio of SD to mean)                            \<50%: 1 \>50%: 0                For quantitative measure, large standard deviation may imply poor precision or large intra-group variations, which is regarded to have lower study quality.
  6\.   Statistical method                                         Appropriate: 1 Questionable: 0   Questionable statistical analyses include the use of unpaired test for paired samples, parametric test for ordinal data with a few ranks, the use of unadjusted multiple comparisons instead of ANOVA or Kruskal-Wallis test.
  7\.   Description of selection region of interest                Yes: 1 No: 0                     For histology/imaging outcome measure, description of systematic/random sampling of region of interest is considered to provide better study quality.
  8\.   Semiquantitative scoring/image analysis                    Yes: 1 No: 0                     For histology/imaging outcome measure, implementation of scoring systems or image analysis protocol is considered to provide better study quality.

*^a^*ACLR, anterior cruciate ligament reconstruction; ANOVA, analysis of variance; SD, standard deviation.

Results {#section5-2325967114526687}
=======

Search Results {#section6-2325967114526687}
--------------

In the original search, titles of 2424 studies were screened from the systematic searches; 2070 articles were filtered out with the absence of the keywords *reconstruction*, *reconstructive*, or *healing*. After applying exclusion criteria on the remaining 354 articles based on article type and study type, 254 articles were left. Fifty-nine studies included the use of biomaterials that did not involve biological modulation; 141 studies involved biological modulation that did not primarily promote healing (ie, pain relief, infection). Based on inclusion criteria, 54 studies were identified as clinical studies or animal studies that involved biological modulation to promote graft healing in ACLR. Screening the titles of the filtered 2070 articles further yielded 8 articles that might meet inclusion criteria. These studies used *ACL surgery*, *bone-tendon healing*, *wound*, *injury*, or *ACL* instead of *healing/reconstruction* in the titles. The abstracts of the 62 included articles were screened. Three studies were later excluded owing to duplication in Chinese and English literature with the same study design. Seven studies focused on biological modulation on intact ACLs and were thus excluded. One study was excluded because of a lack of a control group. One study was excluded since the full text was unavailable. Fifty studies were therefore included for data extraction and critical appraisal on study quality. In the updated search carried out in January 2014, out of the 331 studies, 199 studies were excluded based on the absence of the keywords *reconstruction*, *reconstructive*, or *healing*, and 22 duplicate studies were removed. After screening the titles of the remaining 110 articles and applying the exclusion criteria based on article type and study type, only 10 studies were included for data extraction.

Data Extraction {#section7-2325967114526687}
---------------

The study characteristics of both the original and updated search are provided in [Table 2](#table2-2325967114526687){ref-type="table"}. Of the 60 included studies, 3 tested the effects of biophysical intervention; 11 tested the effects of cells alone or in combination with growth factors or scaffold, 37 evaluated growth factors or drugs with or without biomaterials, and 9 evaluated the biological effect of biomaterials. Ten clinical studies were included; 2 tested the effects of biophysical intervention and 8 investigated growth factors or drugs. More than half of the animal studies (n = 31) utilized a rabbit model, 8 studies used dogs, 3 studies used sheep, 6 studies used rats, 1 study used a porcine, and 1 study used a goat model. Most included studies involved ACLR surgery, except 6 studies that used animal models of ACL partial lesion and 1 on overstretched ACL injury. Various types of grafts were used in the included studies. Both hamstring and bone-tendon-bone (BTB) grafts were used in the clinical studies. In rabbit models, semitendinosus and extensor grafts were preferred but other graft types were also used. There were no preferred graft types in studies on dogs, and the graft preference was not clear in sheep, goat, or rat models because of the small sample sizes. Two animal studies investigated the effect of biological modulation on allografts, and 2 animal studies evaluated artificial grafts. The maximum follow-up time was 12 months in both clinical and animal studies. Most studies reported positive effects with the biological modulation under investigation; 6 studies reported no difference, and only 2 animal studies reported negative effects with platelet-rich plasma (PRP) and vascular endothelial growth factor (VEGF), respectively. Among the 6 reports of no difference, 3 evaluated platelet factors, 2 biomaterials, and 1 bone marrow concentrate.

###### 

Search Results of Studies Investigating Biological Modulation of Healing in ACL Reconstruction^*a*^

![](10.1177_2325967114526687-table2)

  Year/Author                                            Biological Modulation                                        Type          Human/Animal      n     Surgery/Graft        Follow-up, Min-Max         Outcome Measures                    Finding         Evidence Level   Quality Score
  ------------------------------------------------------ ------------------------------------------------------------ ------------- ----------------- ----- -------------------- -------------------------- ----------------------------------- --------------- ---------------- ---------------
  2014/Silva et al^[@bibr54-2325967114526687]^           Bone marrow concentrate                                      GF/drugs      Clinical          43    ACLR/HS, DB          3 mo                       Imaging                             No difference   2                4/10
  2013/Zhang et al^[@bibr73-2325967114526687]^           Autologous bone marrow                                       GF/drugs      Rabbit            32    ACLR/ ST             2 wk--12 wk                Histology, mech                     Positive        B                5/8
  2013/Zhai et al^[@bibr69-2325967114526687]^            PRP and demineralized bone protein                           GF/drugs      Rabbit            48    ACLR/ST              2 wk--4 wk-- 8 wk--12 wk   Histology, mech, imaging            Positive        B                5/8
  2013/Xie et al^[@bibr65-2325967114526687]^             PRP                                                          GF/drugs      Dog               36    ACLR/Flex            2 wk--12 wk                Biochem                             Positive        C                1/8
  2013/Weimin et al^[@bibr62-2325967114526687]^          Calcium phosphate cement with bone xenograft/BMP composite   GF/drugs      Rabbit            90    ACLR/EXT             6 wk--24 wk                Histology, mech, imaging            Positive        B                3/8
  2013/Oka et al^[@bibr43-2325967114526687]^             Simvastatin-conjugated gelatin hydrogel                      GF/drugs      Rabbit            42    ACLR/ HS             2 wk--8 wk                 Histology, mech, imaging            Positive        B                6/8
  2013/Mifune et al^[@bibr39-2325967114526687]^          ACL-derived cell sheet                                       Cell          Rat               27    ACLR/Flex            2 wk--8 wk                 Histology, mech                     Positive        B                4/8
  2013/Lui et al^[@bibr36-2325967114526687]^             Alendronate (systemic)                                       GF/drugs      Rat               84    ACLR/Flex            2 wk--6 wk                 Histology, mech, imaging            Positive        B                7/8
  2013/Lui et al^[@bibr35-2325967114526687]^             Alendronate (local)                                          GF/drugs      Rat               72    ACLR/Flex            2 wk--6 wk                 Histology, mech, imaging            Positive        B                7/8
  2014/Hsu and Wang^[@bibr23-2325967114526687]^          Demineralized bone matrix                                    Biomaterial   Rabbit            10    ACLR/EXT             4 wk--12 wk                Histology, imaging                  Positive        D                5/8
  2013/Cho et al^[@bibr8-2325967114526687]^              Cationized gelatin and hyaluronic acid coating               GF/drugs      Porcine           6     ACLR/PET             3 mo                       Histology, imaging                  Positive        D                5/8
  2012/Shoji et al^[@bibr52-2325967114526687]^           MicroRNA                                                     GF/drugs      Rat               55    ACLT partial         1 wk--4 wk                 Histology, mech, biochem            Positive        B                5/8
  2012/Lee et al^[@bibr32-2325967114526687]^             SIS/PRP                                                      GF/drugs      Rabbit            20    ACLR/braided SIS     1 wk--8 wk                 Histology, mech, imaging            Negative        B                5/8
  2012/Kadonishi et al^[@bibr26-2325967114526687]^       Enamel                                                       Biomaterial   Rat               30    ACLR/Flex            4 wk--12 wk                Histology, mech                     Positive        B                2/8
  2012/Ediz et al^[@bibr14-2325967114526687]^            Electrostimulation                                           Biophy        Clinical          29    ACLR/HS              1 d--6 mo                  Clinical, quest                     Positive        1                8/10
  2012/Dong et al^[@bibr12-2325967114526687]^            BMSC-BMP2 transfected                                        Cell          Rabbit            30    ACLR/GAS             4 wk--8 wk                 Histology, mech                     Positive        B                4/8
  2012/Chen et al^[@bibr7-2325967114526687]^             Periosteum progenitor cell sheet                             Cell          Rabbit            20    ACLR/EXT             8 wk                       Histology, mech                     Positive        B                2/8
  2012/Chen et al^[@bibr6-2325967114526687]^             VEGF in hyaluronan                                           GF/drugs      Rabbit            45    ACLR/BTB Allo        2 wk--8 wk                 Histology, mech                     Positive        B                4/8
  2011/Zhang et al^[@bibr72-2325967114526687]^           Bioactive scaffold                                           Biomaterial   Rabbit            51    ACLR/Flex            12 wk                      Histology, mech, imaging            No difference   B                2/8
  2011/Zhang et al^[@bibr71-2325967114526687]^           Ginseng                                                      GF/drugs      Rabbit            20    ACLR/EXT             4 wk--8 wk                 Histology                           Positive        E                3/8
  2011/Wei et al^[@bibr60-2325967114526687]^             TGF-β/VEGF transfected MSC                                   Cell          Rabbit            176   ACLR/AT              3 wk--24 wk                Histology, mech                     Positive        B                6/8
  2011/Qin et al^[@bibr48-2325967114526687]^             TGF-β plasmid matrix                                         GF/drugs      Rabbit            48    ACLR/ST              1 mo--6 mo                 Histology                           Positive        E                2/8
  2011/Pan et al^[@bibr45-2325967114526687]^             BMP + materials                                              GF/drugs      Rabbit            51    ACLR                 2 wk--12 wk                Histology, mech, imaging            Positive        B                2/8
  2011/Ni et al^[@bibr42-2325967114526687]^              Calcium acid phosphate                                       Biomaterial   Dog               36    ACLR/HS              1 mo--6 mo                 Histology, mech                     Positive        B                1/8
  2011/Mutsuzaki et al^[@bibr41-2325967114526687]^       Calcium phosphate                                            Biomaterial   Goat              18    ACLR/HS, Flex        1 y                        Clinical, lax                       Positive        A                7/8
  2011/Kondo et al^[@bibr30-2325967114526687]^           TGF-β--treated synovial cells                                Cell          Sheep             52    ACLR/ST              1 wk--12 wk                Histology, mech                     Positive        B                5/8
  2011/Hashimoto et al^[@bibr20-2325967114526687]^       BMP2 injection                                               GF/drugs      Rabbit            40    ACLR/ST              4 wk--8 wk                 Histology, mech, imaging            Positive        B                4/8
  2011/Darabos et al^[@bibr9-2325967114526687]^          Autologous conditioned serum                                 GF/drugs      Clinical          62    ACLR/HS, BTB         10 d--12 mo                Imaging, quest, biochem             Positive        1                8/10
  2010/Wang et al^[@bibr59-2325967114526687]^            BMP-transected cells                                         Cell          Rabbit            36    ACLR/EXT             1 wk--12 wk                Histology, mech, imaging            Positive        B                6/8
  2010/Vogrin et al^[@bibr58-2325967114526687]^          PRP                                                          GF/drugs      Clinical          50    ACLR/HS              3 mo--6 mo                 Lax                                 Positive        1                6/10
  2010/Shen et al^[@bibr51-2325967114526687]^            Calcium phosphate ceramics                                   Biomaterial   Rabbit            30    ACLR/ST              4 wk--12 wk                Histology                           Positive        E                2/8
  2009/Wen et al^[@bibr63-2325967114526687]^             Bone cement                                                  Biomaterial   Rabbit            28    ACLR/Flex            6 wk--12 wk                Histology, mech, imaging            Positive        B                2/8
  2009/Silva et al^[@bibr53-2325967114526687]^           PRP                                                          GF/drugs      Clinical          40    ACLR/HS, DB          3 mo                       Imaging                             No difference   2                1/10
  2009/Papatheodorou et al^[@bibr46-2325967114526687]^   LIPUS                                                        Biophy        Rabbit            52    ACLR/EXT             1 d--21 d                  Biochem, histology                  Positive        C                3/8
  2008/Zhang et al^[@bibr70-2325967114526687]^           bFGF                                                         GF/drugs      Dog               14    ACLR/EXT, Allo       1 wk--6 wk                 Histology                           Positive        E                1/8
  2008/Sasaki et al^[@bibr49-2325967114526687]^          Granulocyte stimulating factor                               GF/drugs      Dogs              28    ACLR/Flex            2 wk--4 wk                 Histology, mech, biochem, imaging   Positive        B                2/8
  2008/Orrego et al^[@bibr44-2325967114526687]^          Platelet concentrate + bone plug                             GF/drugs      Clinical          108   ACLR/ST              3 mo--6 mo                 Imaging                             No difference   2                4/10
  2008/Fanton et al^[@bibr16-2325967114526687]^          Ketoprofen, amitriptyline, and oxymetazoline                 GF/drugs      Clinical          35    ACLR/Allo            1 d--30 d                  Clinical, pain                      Positive        1                6/10
  2008/Benazzo et al^[@bibr4-2325967114526687]^          PEMF                                                         Biophy        Clinical          84    ACLR/HS              30 d--180 d                Quest                               Positive        1                4/10
  2008/Babb et al^[@bibr2-2325967114526687]^             MSC                                                          Cell          Immature rabbit   15    ACLR/EXT             3 wk--20 wk                Imaging, histology                  Positive        D                5/8
  2007/Soon et al^[@bibr55-2325967114526687]^            MSC                                                          Cell          Rabbit            36    ACLR/AT              2 wk--8 wk                 Histology, mech                     Positive        B                3/8
  2007/Li et al^[@bibr33-2325967114526687]^              MSC or PDGF-BB--transfected MSC                              Cell          Rabbit            36    ACLR/AT              3 wk--12 wk                Histology                           Positive        E                1/8
  2007/Kanaya et al^[@bibr27-2325967114526687]^          MSC                                                          Cell          Rat               98    ACLT partial         1 wk--4 wk                 Histology, mech                     Positive        B                5/8
  2007/Huangfu and Zhao^[@bibr25-2325967114526687]^      TCP                                                          Biomaterial   Dog               48    ACLR/Flex            2 wk--12 wk                Histology, mech                     Positive        B                3/8
  2007/Huang et al^[@bibr24-2325967114526687]^           Hyaluronic acid                                              GF/drugs      Clinical          120   ACLR/BTB             4 wk--16 wk                Clinical, quest                     Positive        1                4/10
  2006/Yoshikawa et al^[@bibr68-2325967114526687]^       VEGF                                                         GF/drugs      Sheep             18    ACLR/ST              12 wk                      Histology, mech, lax                Negative        B                6/8
  2006/Dynybil et al^[@bibr13-2325967114526687]^         Osteoprotegerin                                              GF/drugs      Rabbit            15    ACLR/ST              3 wk                       Histology, imaging                  Positive        D                6/8
  2005/Yamazaki et al^[@bibr66-2325967114526687]^        TGFβ1                                                        GF/drugs      Dog               21    ACLR/Flex            3 wk                       Histology, mech                     Positive        B                8/8
  2005/Ventura et al^[@bibr57-2325967114526687]^         Growth factor                                                GF/drugs      Clinical          20    ACLR/HS              6 mo                       Imaging, quest, biochem             Positive        1                1/10
  2005/Kondo et al^[@bibr31-2325967114526687]^           TGF-β, PDGF-BB                                               GF/drugs      Rabbit            36    Overstretch injury   12 wk                      Histology, mech, lax                Positive        A                5/8
  2005/Demirag et al^[@bibr11-2325967114526687]^         Blockade of MMP α-2 macroglobulin                            GF/drugs      Rabbit            28    ACLR/ST              2 wk--5 wk                 Hisot, mech, biochem                Positive        B                3/8
  2004/Yasuda et al^[@bibr67-2325967114526687]^          TGF-β + EGF                                                  GF/drugs      Dog               25    ACLR/BTB             12 wk                      Histology, mech                     Positive        A                5/8
  2004/Weiler et al^[@bibr61-2325967114526687]^          PDGF-BB                                                      GF/drugs      Sheep             48    ACLR/Flex            3 wk--24 wk                Histology                           No difference   A                7/8
  2004/Tien et al^[@bibr56-2325967114526687]^            Calcium phosphate cement                                     Biomaterial   Rabbit            22    ACLR/ST              1 wk--24 wk                Histology, mech                     No difference   B                4/8
  2004/Lim et al^[@bibr34-2325967114526687]^             MSC                                                          Cell          Rabbit            48    ACLR/ST              2 wk--8 wk                 Histology, mech                     Positive        B                4/8
  2004/Demirag et al^[@bibr10-2325967114526687]^         α-2 macroglobulin                                            GF/drugs      Rabbit            20    ACLT                 10 d                       Histology                           Positive        E                3/8
  2001/Anderson et al^[@bibr1-2325967114526687]^         Bone growth factor                                           GF/drugs      Rabbit            70    ACLR/ST              2 wk--8 wk                 Histology, mech                     Positive        B                4/8
  1997/Kobayashi et al^[@bibr29-2325967114526687]^       bFGF                                                         GF/drugs      Dog               34    ACLT partial         1 wk--24 wk                Histology                           Positive        E                1/8
  1997/Kikuchi et al^[@bibr28-2325967114526687]^         Hyaluronan                                                   GF/drugs      Rabbit            36    ACLT partial         2 wk--6 wk                 Histology                           Positive        E                4/8
  1990/Wiig et al^[@bibr64-2325967114526687]^            Hyaluronic acid                                              GF/drugs      Rabbit            21    ACLT partial         4 wk--12 wk                Histology                           Positive        E                1/8

*^a^*ACL, anterior cruciate ligament; ACLR, ACL reconstruction; ACLT, ACL transaction; Allo, allograft; AT, Achilles tendon; bFGF, basic fibroblast growth factor; Biochem, biochemical assay; Biophy, biophysical intervention; BMP, bone morphogenetic protein; BMP2, bone morphogenetic protein--2; BMSC, bone marrow--derived mesenchymal stem cell; BTB, bone-tendon-bone; DB, double-bundle; EGF, epidermal growth factor; EXT, extensor; Flex, flexor tendon; GAS, gastrocnemius; GF, growth factor; HS, hamstring tendon; Lax, laxity test; LIPUS, low-intensity pulsed ultrasound; Mech, mechanical test; MMP, matrix metalloproteinase; MSC, mesenchymal stem cell; PDGF-BB, platelet-derived growth factor--BB; PEMF, pulsed electromagnetic fields; PET, polyethylene terephthalate artificial ligament; PRP, platelet-rich plasma; Quest, questionnaire; SIS, small intestine submucosa; ST, semitendinosus; TCP, tricalcium phosphate; TGF-β, transforming growth factor--beta; VEGF, vascular endothelial growth factor.

Methodological Quality Assessment {#section8-2325967114526687}
---------------------------------

The results of the methodological quality assessment are shown in the last 2 columns of [Table 2](#table2-2325967114526687){ref-type="table"}. For clinical studies, 3 were rated as evidence level 2, and the rest were rated as level 1. Four clinical studies scored 6 or higher out of 10 in CASP, while 6 clinical studies scored less than 5 and were considered low quality. For animal studies, 4 studies were ranked "A" regarding clinically relevant quantitative outcome measures, and the methodological scores were all higher than 5 out of 8. Thirty-one animal studies were ranked "B" with the use of mechanical test outcome measures. The methodological score of these studies ranged from 1 to 8, with only 13 studies scoring 5 or higher. Two rank-"C" studies were included with quantitative biochemical outcome measure, and the study quality was low (1 and 3, respectively). Four rank-"D" studies with semiquantitative outcome measures and their methodological score were fair to satisfactory (4 in 1 study, 5 in 2 studies, 6 in 1 study). However, none of the rank-"E" studies scored higher than 4, and all of them were considered low-quality studies. In summary, only 25 included studies were appraised with satisfactory study quality, and further metasynthesis was performed on these studies. Good interobserver reliability was obtained between assessors (S.C.F. and Y.C.C.; intraclass correlation coefficient average measures, 0.848), and consensus on scoring was reached by discussion.

Metasynthesis {#section9-2325967114526687}
-------------

In the 25 good-quality studies (methodological score ≥5), 1 involved the use of biophysical intervention,^[@bibr14-2325967114526687]^ 2 used biomaterials,^[@bibr23-2325967114526687],[@bibr41-2325967114526687]^ 5 involved the use of cells,^[@bibr2-2325967114526687],[@bibr27-2325967114526687],[@bibr30-2325967114526687],[@bibr59-2325967114526687],[@bibr60-2325967114526687]^ and 17 tested the effects of growth factors or drugs.^[∥](#fn1-2325967114526687){ref-type="fn"}^ Four animal studies found positive results with the use of transforming growth factor--beta (TGF-β) in different combinations to promote bone-tendon junction healing.^[@bibr31-2325967114526687],[@bibr48-2325967114526687],[@bibr66-2325967114526687],[@bibr67-2325967114526687]^ Three animal studies tested the effects of VEGF-mediated angiogenesis, but the results were inconsistent.^[@bibr6-2325967114526687],[@bibr60-2325967114526687],[@bibr68-2325967114526687]^ Two animal studies tested the effects of platelet-derived growth factor--BB (PDGF-BB) and reported positive findings.^[@bibr31-2325967114526687],[@bibr61-2325967114526687]^ The use of bone morphogenetic protein (BMP)-transfected cells,^[@bibr59-2325967114526687]^ osteoprotegrin,^[@bibr13-2325967114526687]^ calcium phosphate,^[@bibr25-2325967114526687],[@bibr41-2325967114526687],[@bibr51-2325967114526687]^ and demineralized bone matrix^[@bibr23-2325967114526687]^ primarily targeted osteogenesis inside the bone tunnel, and positive findings were reported. The use of bisphosphonate-targeted inhibition of bone resorption yielded similar effects.^[@bibr35-2325967114526687],[@bibr36-2325967114526687]^ One clinical study observed beneficial effects of PRP,^[@bibr58-2325967114526687]^ but in another animal study, PRP exerted negative effects in the context of small intestine submucosa (SIS) artificial graft.^[@bibr32-2325967114526687]^ Two animal studies revealed the beneficial effects of supplementation of mesenchymal stem cells (MSCs) alone.^[@bibr2-2325967114526687],[@bibr27-2325967114526687]^ Three clinical studies reported improvements in knee functions and pain score with control of postsurgical local inflammation and swelling by electrostimulation,^[@bibr14-2325967114526687]^ intra-articular injection of autologous serum for interleukin--1 beta (IL-1β) antagonization,^[@bibr9-2325967114526687]^ or drug formulation in arthroscopic irrigation saline for allograft ACLR,^[@bibr16-2325967114526687]^ whereas 1 animal study reported alleviating inflammation by cationized gelatin and hyaluronic acid coating on artificial graft, which could improve healing at the bone-graft interface.^[@bibr8-2325967114526687]^

With respect to outcome measures, 2 clinical studies achieved improved pain and knee functions,^[@bibr14-2325967114526687],[@bibr16-2325967114526687]^ while another reported significant improvements in imaging and biochemical outcome measures.^[@bibr9-2325967114526687]^ All good-quality animal studies used mechanical tests of pull-out strength of the graft complex as the key outcome except 4 studies, which only reported histological findings alone or together with imaging findings.^[@bibr2-2325967114526687],[@bibr8-2325967114526687],[@bibr13-2325967114526687],[@bibr61-2325967114526687]^ One study in a sheep model evaluated healing outcomes with in situ force and knee laxity.^[@bibr68-2325967114526687]^ All good-quality studies involved ACLR surgery except 3, which investigated ACL partial lesions in rats^[@bibr27-2325967114526687],[@bibr52-2325967114526687]^ or focused on overstretched ACL injury in rabbits.^[@bibr31-2325967114526687]^

Discussion {#section10-2325967114526687}
==========

Proposed Mechanism {#section11-2325967114526687}
------------------

This systematic review shows that there is good evidence for biological modulation to promote healing in ACLR. The proposed mechanisms for the biological modulation fell into 5 categories: (1) bone-tendon healing at the graft-tunnel interface, (2) angiogenesis, (3) osteogenesis, (4) cell supplementation for general healing capacity, and (5) reduction of local inflammation.

Although the intra-articular midsubstance would be the weakest link of the graft-complex in ACLR, tendon-bone healing at tunnel interface was the target of most biological modulation. Notably, the roles of TGF-β on bone-tendon junction healing have been well demonstrated in other animal models,^[@bibr37-2325967114526687]^ thus it is not surprising to see the effectiveness of TGF-β in promoting graft incorporation in ACLR. Since tunnel widening is an adverse healing outcome of ACLR, strategies that promote osteogenesis or reduce bone resorption also worked to improve the pull-out strength of the graft complex. Studies of cell supplementation also targeted the graft-tunnel interface. However, overall improvement was limited by graft deterioration at the intra-articular space. Strategies to reduce graft deterioration by reducing local inflammation or direct modulation on degradative enzymes^[@bibr10-2325967114526687],[@bibr11-2325967114526687]^ may be complementary to treatment that targeted tunnel interface healing. From the search results, only 1 included study^[@bibr16-2325967114526687]^ used nonsteroidal anti-inflammatory drugs (NSAIDs) as one of the components in the treatment formula. Based on the current search results, it is difficult to conclude that NSAIDs should be used freely for pain control without affecting knee function. However, as inflammation is necessary for the early healing phase and excessive inflammation may hamper the healing outcome, it is critical to control the extent of inflammation. The use of NSAIDs to control excessive inflammation without affecting knee function would be a primary concern for clinicians. With respect to angiogenesis, the current evidence is not consistent, especially with respect to the effects of VEGF. Revascularization would be essential to graft survival, but vascular invasion into the graft may also cause graft weakening. In summary, the current evidence suggests that biological modulation benefited healing by promoting graft incorporation at the tunnel interface, and further works on reducing graft deterioration may be worthwhile.

Practical Significance {#section12-2325967114526687}
----------------------

For all included animal studies, the pull-out strength of the graft complex in the untreated control group was around 10% of the ultimate strength of the intact ACL, and the improvement by biological modulation was around 22% at maximum. As the clinical graft failure rate for ACLR is around 8%, the practical significance of the improvement in pull-out strength is questionable. However, as ACL in situ force during walking/descending stairs approached 7.8%/20% of ACL ultimate load,^[@bibr40-2325967114526687]^ the improvement may help a little to avoid rerupture during daily activities. Knee laxity measurement and knee function scores are routinely used in clinical settings. However, only a few animal studies measured knee laxity and knee functions. Clinical studies showed that treatment delivered intraoperatively or during early healing phases could improve knee function at later time points, indicating the potential of biological modulation of postoperative local inflammation for long-term functional recovery. From the results of the systematic search, we found the maximum follow-up time point is 12 months. Since graft healing after ACL reconstruction is a lengthy process, a longer follow-up of 2 years would better reveal the effectiveness of the treatment modalities.

Representativeness of Animal Models {#section13-2325967114526687}
-----------------------------------

Currently available clinical studies on biological modulation of ACLR only tested the effects of biophysical intervention, autologous growth factor mixtures, or marketed drugs. The effectiveness of growth factors, cells, and biomaterials was only shown in animal studies, and their validity depends on the representativeness of the animal models. It has been demonstrated that there are significant anatomical differences in ACLs between human and experimental animals,^[@bibr47-2325967114526687]^ and the obvious variations in gait and posture defined the differences of the biomechanical properties. However, there is also evidence about the homology of regenerative responses in mammals and the similar patterns of innervation found in knee joint ligaments.^[@bibr38-2325967114526687]^ Thus, animal studies of ACLR may still convey useful information for further development but extrapolation of preclinical data may need further scrutiny, say, taking a plurispecies approach to confirm the findings.

Factors That Modify Treatment Effects {#section14-2325967114526687}
-------------------------------------

It is well accepted that evaluation of treatment effects should consider time of application and time of evaluation, dose response, and other ancillary conditions such as rehabilitation and activity levels. As most included animal studies did not include investigation of dose response, the observed treatment effects could not be further confirmed. Moreover, all studies of biological modulation of ACLR used intraoperative delivery except those with biophysical intervention. This is likely because of the practical difficulties of noninvasive delivery of the biological agents during the lengthy postoperative recovery phase. As graft healing in ACLR involves different stages such as inflammation, cell recruitment, revascularization, matrix remodeling for graft incorporation, and ligamentization, there is no doubt that different types of biological augmentation may be needed at different healing stages. Therefore, it is not surprising that positive treatment effects were only observed at early time points but not at later time points as the intraoperative treatment effects would have been faded out.

Analysis of Reporting Biases {#section15-2325967114526687}
----------------------------

This systematic review may be subject to publication bias as most of the included studies reported improvement (52 positive findings, 6 no difference, and 2 negative findings). Only 3 studies with positive results received commercial sponsorship, and their findings did not stand out from similar studies.^[@bibr1-2325967114526687],[@bibr4-2325967114526687],[@bibr16-2325967114526687]^ We are certain that there are unpublished studies on biological modulation in ACLR, as shown in the conference abstracts at the Annual Meeting of the Orthopaedic Research Society. Besides, studies in gray literature are difficult to access using the current search strategy. To our knowledge, there are relevant studies published in new journals that are not included in the 3 search databases.^[@bibr17-2325967114526687]^ Because we identified good-quality studies with an arbitrary cutoff score (≥5), it is likely that we may have missed some meaningful findings during the integration of clinical/experimental evidence. If we lowered the cutoff scores to 4, 12 studies would be further included. These studies revealed similar findings according to the mechanisms to promote healing. However, 2 studies reported the positive effects of hyaluronan with repeated intra-articular injection,^[@bibr24-2325967114526687],[@bibr28-2325967114526687]^ which may represent a different mechanism for biological modulation of ACLR.

Further Steps to Modify the Current Clinical Practice {#section16-2325967114526687}
-----------------------------------------------------

Before implementing any biological interventions, it is important to have evidence of their effectiveness for ACLR. Further research is required to determine the necessity and timing of the interventions. From the clinical studies with reasonably good study quality (score 6-8 out of 10 in CASP), there is evidence that short-term clinical outcomes after ACLR were improved by preparations of growth factors,^[@bibr9-2325967114526687],[@bibr58-2325967114526687]^ drugs,^[@bibr16-2325967114526687]^ or electrostimulation.^[@bibr14-2325967114526687]^ Most of these interventions improved outcomes related to postsurgical pain response, except 1 study with platelet gel that showed improvement in anterior-posterior knee laxity. These studies suggest that intra-operative interventions targeted to reduce inflammation or promote graft healing are beneficial for recovery after ACLR. Moreover, many preclinical experimental evidences suggested that healing outcome could be further improved with biological modulation. Thus, translational research to bring preclinical findings into good-quality clinical trials is essential for the use of effective biological modulation to improve healing outcomes in a clinical setting. The major trend in ACLR is modification of surgical procedures such as the use of different types of tendon grafts and fixation methods.^[@bibr3-2325967114526687],[@bibr19-2325967114526687],[@bibr21-2325967114526687]^ Although this review showed great potential, biological modulations are still in the exploratory stage. More evidence from both preclinical and clinical studies is required for implementation in clinical practice.
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